Revenue ($USD) : $350,852,000 R&D spend : $44,033,000.00 Employees : 705 Fiscal year end : 12/31/22 CEO : Patrick Miles
Alphatec Holdings specializes in the manufacturing of spinal implant and tissue technologies for spine surgery procedures. Alphatec CEO Patrick Miles says its 100% spine focus provides a competitive edge in developing procedural-based medical devices optimized for surgeon adoption and procedural volume. Strong revenue drivers include its proprietary prone transpsoas surgery (PTP) and lateral transpsoas (LTP) access systems. In 2023, Alphatec acquired a navigation-enabled robotics platform and debuted an anterior lumbar interbody fusion (ALIF) access system. –BB
